Capstone Investment Advisors LLC Makes New $708,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Capstone Investment Advisors LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 35,607 shares of the biopharmaceutical company's stock, valued at approximately $708,000.

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 681 shares during the period. nVerses Capital LLC acquired a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at about $50,000. Larson Financial Group LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 2,994 shares during the period. CWM LLC boosted its stake in shares of Catalyst Pharmaceuticals by 686.5% in the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company's stock worth $63,000 after buying an additional 3,549 shares during the last quarter. Finally, Meeder Asset Management Inc. acquired a new stake in Catalyst Pharmaceuticals during the second quarter worth about $70,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Down 1.2 %

Shares of NASDAQ CPRX traded down $0.27 during midday trading on Friday, hitting $22.07. The stock had a trading volume of 554,311 shares, compared to its average volume of 1,187,151. Catalyst Pharmaceuticals, Inc. has a 1 year low of $13.00 and a 1 year high of $24.27. The company has a market capitalization of $2.63 billion, a PE ratio of 18.93, a P/E/G ratio of 3.44 and a beta of 0.75. The stock has a 50 day simple moving average of $21.23 and a 200-day simple moving average of $18.72.

Analyst Ratings Changes

Several equities research analysts have commented on CPRX shares. Stephens assumed coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an "overweight" rating and a $35.00 price objective on the stock. Truist Financial lifted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a report on Monday, November 11th. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, August 9th. Citigroup lifted their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $31.14.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.